Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Hansa Biopharma
HNSA
Hansa Biopharma
European Organ Allocation Will Face Volatility Yet Allow Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 32.00
3.1% overvalued
intrinsic discount
16 Aug
SEK 33.00
Loading
1Y
-37.4%
7D
14.0%
Author's Valuation
SEK 32.0
3.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 32.0
3.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-802m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue SEK 1.4b
Earnings SEK 303.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
44.61%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.28%
Calculation
SEK 303.52m
Earnings '28
x
20.39x
PE Ratio '28
=
SEK 6.19b
Market Cap '28
SEK 6.19b
Market Cap '28
/
165.53m
No. shares '28
=
SEK 37.39
Share Price '28
SEK 37.39
Share Price '28
Discounted to 2025 @ 5.33% p.a.
=
SEK 32.00
Fair Value '25
